Bioinformatics, Clinical Research and Pharmacokinetics

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioinformatics

Clinical Research

Pharmacokinetics

Biochemical assays and deep cyclic inhibition in cancer treatment

Drug Target Review

JULY 12, 2023

The clinical-stage oncology company develops medicines for broad populations of cancer patients and aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway, selectively impacting cancer cells while sparing healthy cells.

Biochemical Assays

Biochemical Assays Treatment Bioinformatics Disease

Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

The Pharma Data

SEPTEMBER 1, 2020

study investigator and Professor of Clinical Neurology, University of California San Francisco (UCSF) Weill Institute for Neurosciences and clinical research director, UCSF MS Center. Inhibition of drug transporter breast cancer resistance protein has no effect on the pharmacokinetics of major active metabolites of ozanimod.

Clinical Trials

Clinical Trials Treatment Trials Disease

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Drug Discovery Digest

Biochemical assays and deep cyclic inhibition in cancer treatment

Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

Webinars

Stay Connected